Manufacturing cost gap closing among U.S., India, China

U.S. drugmakers have unrealistic expectations of the cost savings they can get by manufacturing in India, says an Indian pharmaceutical exec. The playing field is now level between the two countries, given that equipment and regulatory compliance costs are the same and India's top scientists are earning $90,000 per year.

India still has lower labor costs, but that advantage is partially offset by infrastructure shortcomings, reports the Washington Post.  It also cites an outsourcer for big pharma who predicts his labor cost savings compared with the U.S.--50 percent--could disappear within five years.

In China, meanwhile, the labor cost advantage is beginning to disappear too, thanks to inflation, accompanied by a reduction in government investment and tax rebates. Last fall, A. T. Kearney consultants projected the cost benefit may be negligible in some cases by 2015.

- see the Washington Post story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.